Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Nektar Therapeutics (NQ: NKTR)
9.240 USD  -0.490 (-5.04%)
Official Closing Price  /  Updated: 4:30 PM EDT, May 22, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Nektar Therapeutics
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013
May 21, 2013
from Business Wire News Releases
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
May 16, 2013
from PR Newswire
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
May 09, 2013
from PR Newswire
Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
May 02, 2013
from PR Newswire
Critical Alerts For Intel, Delta, Southern Copper, Lam Research, and Nektar Therapeutics Released By InvestorsObserver
April 17, 2013
from PR Newswire
Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
April 16, 2013
from PR Newswire
Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
April 07, 2013
NKTR-214 Demonstrates Improved Efficacy in Resistant Preclinical Melanoma Model Through Preferential Activation of Tumor Killing Immune Cell Subtype Read More
from PR Newswire
New Programs Designed to Speed up Approval Process a Key Factor in Biotech Industry's Growth in 2012
March 19, 2013
Five Star Equities Provides Stock Research on ImmunoCellular and Nektar Read More
from Marketwired News Releases
Pushing Pipelines Forward for Long-Term Success - Research Report on Vertex, Santarus, Arena Pharmaceuticals, Seattle Genetics and Nektar Therapeutics
March 08, 2013
from PR Newswire
Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
March 01, 2013
from PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
February 28, 2013
from PR Newswire
AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
February 26, 2013
from PR Newswire
Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets
February 13, 2013
from PR Newswire
Number of FDA Drug Approvals Reach a 15-Year High in 2012
February 07, 2013
Research Driven Investing Provides Stocks Research on Nektar Therapeutics and Threshold Read More
from Marketwired News Releases
Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSC
February 05, 2013
from PR Newswire
The Real Story Behind AMBS, ARNA, NKTR and URS
January 23, 2013
from Marketwired News Releases
Record Levels of Available Cash and Moderate R&D Development Will See Big Pharma M&A Activity Increase in 2013
January 16, 2013
Five Star Equities Provides Stock Research on Nektar Therapeutics and Santarus Read More
from Marketwired News Releases
Our Pros Knew HMSY, NKTR, TTM and HSP Would Be Top Gainers on Wednesday
January 10, 2013
from Marketwired News Releases
The Real Story Behind NUVA, NKTR, HOLX and VOLC
January 10, 2013
from Marketwired News Releases
Baxter to Initiate Late-Stage Clinical Trial of BAX 855 for the Treatment of Hemophilia A
January 07, 2013
from Business Wire News Releases
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
January 04, 2013
from PR Newswire
Improving Trend in FDA First Cycle Review Approvals a Major Factor for Biotech Industry's Success in 2012
November 22, 2012
Five Star Equities Provides Stock Research on Nektar Therapeutics and XOMA Read More
from Marketwired News Releases
Research Reports on Top Stocks: Verizon, Nokia, CYS Investments, Prospect Capital, Huntington Bancshares, and Nektar Therapeutics
November 15, 2012
from PR Newswire
Free Research Reports on ARRY, CECO, GILD and NKTR Issued by the Bedford Report
November 13, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
November 12, 2012
from PR Newswire
Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
November 12, 2012
Call Scheduled for Monday, November 12, 2012 at 8:15 AM EST/5:15 AM PST Read More
from PR Newswire
Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
November 07, 2012
from PR Newswire
Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
November 06, 2012
from PR Newswire
GreeneStone Seeks Amex Listing – New Report Confirms Demand
October 18, 2012
from Business Wire News Releases
Nektar Presents Positive Preclinical Data for NKTR-171, A Novel Sodium Channel Blocker to Treat Neuropathic Pain, at 41st Annual Meeting of the Society for Neuroscience
October 15, 2012
NKTR-171 Demonstrates Dose-Dependent Analgesia with Significantly Reduced CNS-Related Side Effects in Preclinical Studies Read More
from PR Newswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here